These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21407224)

  • 1. Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.
    Thiel U; Pirson S; Müller-Spahn C; Conrad H; Busch DH; Bernhard H; Burdach S; Richter GH
    Br J Cancer; 2011 Mar; 104(6):948-56. PubMed ID: 21407224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
    Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
    Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
    Schirmer D; Grünewald TG; Klar R; Schmidt O; Wohlleber D; Rubío RA; Uckert W; Thiel U; Bohne F; Busch DH; Krackhardt AM; Burdach S; Richter GH
    Oncoimmunology; 2016 Jun; 5(6):e1175795. PubMed ID: 27471654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.
    Yu Q; Zhang L; Ouyang L; Gong Y; Liang Z; Shen G; Weng X; Wu X
    Immunogenetics; 2013 Mar; 65(3):173-84. PubMed ID: 23233149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
    Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
    Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
    Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
    Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.
    Altvater B; Kailayangiri S; Theimann N; Ahlmann M; Farwick N; Chen C; Pscherer S; Neumann I; Mrachatz G; Hansmeier A; Hardes J; Gosheger G; Juergens H; Rossig C
    Cancer Immunol Immunother; 2014 Oct; 63(10):1047-60. PubMed ID: 24973179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
    Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
    Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 Inhibition in Ewing Sarcoma Upregulates G
    Kailayangiri S; Altvater B; Lesch S; Balbach S; Göttlich C; Kühnemundt J; Mikesch JH; Schelhaas S; Jamitzky S; Meltzer J; Farwick N; Greune L; Fluegge M; Kerl K; Lode HN; Siebert N; Müller I; Walles H; Hartmann W; Rossig C
    Mol Ther; 2019 May; 27(5):933-946. PubMed ID: 30879952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer.
    Amir AL; van der Steen DM; van Loenen MM; Hagedoorn RS; de Boer R; Kester MD; de Ru AH; Lugthart GJ; van Kooten C; Hiemstra PS; Jedema I; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
    Clin Cancer Res; 2011 Sep; 17(17):5615-25. PubMed ID: 21771875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
    Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
    J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
    Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
    J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.